CRISPR, Star Trek-Like Testing Devices, and Antibiotic Resistance a Focus at Clinical Diagnostics Convention … – PR Newswire (press release)
|
CRISPR, Star Trek-Like Testing Devices, and Antibiotic Resistance a Focus at Clinical Diagnostics Convention …
PR Newswire (press release) ROCKVILLE, Md., July 27, 2017 /PRNewswire/ — Say it three times fast: “Clustered regularly interspaced short palindromic repeats” —Or better known as CRISPR. This gene-editing technology will be a key feature of the world’s largest gathering of lab … |
|
Two Gene Therapy Approaches Pending Approval from FDA Bring Hope to Mesothelioma Community
MesotheliomaHelp.org (blog) Nearly five years ago, MesotheliomaHelp reported about a breakthrough treatment called gene therapy. At the time, it was touted as the “next frontier” in medicine, and cancer patients from around the world watched closely in the hopes that the … |
|
Two Gene Therapy Approaches Pending Approval from FDA Bring Hope to Mesothelioma Community
MesotheliomaHelp.org (blog) Nearly five years ago, MesotheliomaHelp reported about a breakthrough treatment called gene therapy. At the time, it was touted as the “next frontier” in medicine, and cancer patients from around the world watched closely in the hopes that the … |
City A.M. |
AstraZeneca Shares Plunge 16 Percent as Lung Cancer Study Fails
New York Times LONDON — AstraZeneca’s combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, sending its shares plunging on Thursday. The so-called MYSTIC study was the most anticipated … Shares in pharma giant AstraZeneca plunge more than 15% after lung cancer drug trial setbackBusiness Insider AstraZeneca Shares Crash the Most on Record After Key Cancer Drug FailsTheStreet.com Astra plunges as vital cancer drug fails trialEvening Standard Financial Times all 35 news articles » |
|
Immunotherapy setback for AstraZeneca
Seeking Alpha AstraZeneca (NYSE:AZN) -15% premarket after the trial of its new lung cancer drug failed to reach its “endpoints” for progression free survival – the length for which people go without their condition worsening. The study, known as Mystic, featured an … |